OncoMatch/Clinical Trials/NCT07755436
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
Is NCT07755436 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies ARR-002 for ovarian cancer.
Treatment: ARR-002 — This is a Phase 1 study to assess safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ARR-002 in advanced or metastatic ovarian or endometrial cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Endometrial Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
The score of Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Demographics
Prior therapy
Cannot have received: auristatin-derived drug (MMAE, monomethyl auristatin F (MMAF))
Prior treatment with auristatin-derived drugs s (eg, MMAE and monomethyl auristatin F [MMAF])
Cannot have received: MUC16-targeting agent
Prior treatment with MUC16- or NaPi2b-targeting agents
Cannot have received: NaPi2b-targeting agent
Prior treatment with MUC16- or NaPi2b-targeting agents
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- NEXT Oncology · Irving, Texas
- NEXT Oncology · Fairfax, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07755436 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior auristatin-derived drug, MUC16-targeting agent, NaPi2b-targeting agent disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages